Glioblastoma multiforme (GBM) displays cellular hierarchies harboring a subpopulation of
stem-like cells (GSCs). Enhancer of Zeste Homolog 2 (EZH2), the lysine methyltransferase …

Epigenetic modifications in cancer stem cells largely result in phenotypic and functional
heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste …

Accumulating evidence suggests that glioma stem cells (GSCs) are important therapeutic
targets in glioblastoma (GBM). In this study, we identified NIMA-related kinase 2 (NEK2) as a …

EZH2 is frequently overexpressed in glioblastoma (GBM), suggesting an oncogenic function
that could be a target for therapeutic intervention. However, reduced EZH2 activity can also …

Overexpression of the polycomb group protein enhancer of zeste homologue 2 (EZH2)
occurs in diverse malignancies, including prostate cancer, breast cancer, and glioblastoma …

Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of Polycomb repressive
complex 2 that catalyzes the trimethylation of histone H3 on Lys 27, and represses gene …

Enhancer of zeste homolog 2 (EZH2) is the catalytic unit of polycomb repressive complex 2
(PRC2) which epigenetically silences many genes involved in tumor-suppressive …

The most aggressive of four medulloblastoma (MB) subgroups are cMyc-driven group 3 (G3)
tumors, some of which overexpress EZH2, the histone H3K27 mono-, di-, and trimethylase of …

EZH2 is the histone H3 lysine 27 methyltransferase of polycomb‐repressive complex 2. It
transcriptionally silences cohorts of developmental regulators in stem/progenitors and …

F. Orzan, S. Pellegatta, PL Poliani, F. Pisati, V. Caldera, F. Menghi, D. Kapetis, C. Marras, D.
Schiffer and G. Finocchiaro (2011) Neuropathology and Applied Neurobiology37, 381–394 …